) recently presented data from various studies on its oncology
drugs at the annual meeting of the American Society of Clinical
Oncology (ASCO) held in the US.
ALEXION PHARMA (ALXN): Free Stock Analysis
CUBIST PHARM (CBST): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
To read this article on Zacks.com click here.
Celgene presented detailed data from the MPACT (Metastatic
Pancreatic Adenocarcinoma Clinical Trial) study (n=861), which
evaluated its oncology drug Abraxane in combination with
Eli Lilly and Company
) Gemcitabine as a first-line therapy in patients suffering from
advanced pancreatic cancer.
Data from the study revealed that there was significant
improvement in overall survival in patients treated with Abraxane
and Gemzar compared to those treated with Gemzar alone. The
median progression-free survival of 8.5 months was observed in
the Abraxane plus Gemzar arm compared to 6.7 months for patients
in the Gemzar arm.
We note that Abraxane is under priority review in the US for the
advanced pancreatic cancer indication. Abraxane in combination
with Gemzar is also under review in the EU for the same
Celgene also presented data from a study, which evaluated its key
oncology drug Revlimid as a combination therapy versus autologous
stem cell transplant with or without Revlimid maintenance in
newly-diagnosed multiple myeloma (MM) patients.
Data revealed a longer median progression-free survival and
overall survival rate for patients in the stem cell transplant
arm compared to those treated with the Revlimid combination.
Moreover, maintenance therapy with Revlimid resulted in a
statistically significant reduction in the risk of disease
progression while causing improvement in overall survival
irrespective of prior therapy.
Celgene also presented encouraging updated data from an
international late-stage study (MM-003) which evaluated Pomalyst
combined with low-dose dexamethasone versus high-dose
dexamethasone in previously treated MM patients. Data from a
study (MM-008) evaluating Pomalyst in patients suffering from
renal impairment was also presented by Celgene at the ASCO.
Celgene, a biopharmaceutical company, currently carries a Zacks
Rank #2 (Buy).
Alexion Pharmaceuticals, Inc.
Cubist Pharmaceuticals, Inc.
) look equally attractive in the biopharma space with a Zacks
Rank #2 each.